Abstract PS11-05: Updated data from SERENA-1: A Phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and …

R Baird, M Oliveira, EMC Gil, MR Patel… - Cancer research, 2021 - AACR
Background: AZD9833 is an oral selective estrogen receptor (ER) antagonist and degrader
(SERD) in Phase 2 clinical development for the treatment of ER+ HER2− breast cancer …
Save Cite Cited by 32 Related articles All 3 versions

Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal …

HM Moore, V Boni, M Bellet, B Bermejo De Las Heras… - 2021 - ascopubs.org
577 Background: Modulation of ER activity and/or estrogen synthesis is the mainstay
therapeutic strategy in ER+ BC treatment. Giredestrant is a highly potent, nonsteroidal oral …
Save Cite Cited by 15 Related articles
[HTML] oup.comFull View

A phase II prospective, randomized, double‐blind, placebo‐controlled and multicenter clinical trial to assess the safety of 0.005% estriol vaginal gel in hormone …

P Sánchez‐Rovira, AL Hirschberg, M Gil‐Gil… - The …, 2020 - academic.oup.com
Abstract Lessons Learned The levels of circulating follicle‐stimulating hormone, luteinizing
hormone, estriol, estradiol, and estrone remained unchanged after a 12‐week treatment with …
Save Cite Cited by 15 Related articles All 9 versions Full View
[HTML] springer.com

[HTML][HTML] Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the …

A Llombart-Cussac, A Prat, JM Pérez-García… - European Journal of …, 2024 - Springer
Abstract Background The PHERGain study (NCT03161353) is assessing early metabolic
responses to neoadjuvant treatment with trastuzumab-pertuzumab and chemotherapy de …
Save Cite Related articles All 3 versions
[HTML] nih.gov

The economic burden of metastatic breast cancer in Spain

BB de Las Heras, JCR y Cajal, EG Calvo… - European Journal of …, 2020 - ejhp.bmj.com
Objectives The study aimed to estimate the burden of metastatic breast cancer (mBC) in
Spain over 5 years. Methods An incidence-based cost-of-illness model was developed in …
Save Cite Cited by 9 Related articles All 5 versions

miR-503-5p induces doxorubicin resistance in triple-negative breast cancer.

I Garrido-Cano, A Adam-Artigues, A Lameirinhas… - 2021 - ascopubs.org
1083 Background: Triple-negative breast cancer (TNBC) is an aggressive breast cancer
(BC) subtype comprising approximately 15% of BC. Conventional cytotoxic chemotherapies …
Save Cite Related articles

Cáncer de mama y embarazo. Análisis de una serie de 27 pacientes

AM Oltra, AC Garate, JC Chornet, AP Fidalgo… - Revista de Senología y …, 2012 - Elsevier
Objetivo Realizar un análisis descriptivo de la serie de pacientes con cáncer de mama (CM)
y embarazo diagnosticadas en nuestro centro en relación con los métodos terapéuticos …
Save Cite Cited by 1 Related articles All 2 versions

Hormonoterapia adyuvante en mujeres postmenopáusicas

BB de las Heras, IC González, A Bosch… - Revisiones en …, 2009 - dialnet.unirioja.es
La hormonoterapia constituye uno de los pilares fundamentales del tratamiento del
carcinoma de mama (CM). En los últimos años se han producido grandes avances en el …
Save Cite Cited by 2 Related articles Cached

Cáncer de mama en la mujer anciana

MTM Martínez, MT Céspedes, CH Meliá… - Revisiones en …, 2021 - dialnet.unirioja.es
El cáncer de mama sigue siendo el tumor más frecuente en la mujer y el aumento de la
esperanza de vida en los últimos años hace que actualmente el cáncer de mama en la …
Save Cite Related articles Cached

Un paso más en el cáncer de mama triple negativo precoz: inmunoterapia

BB de las Heras - Revisiones en cáncer, 2023 - oncomedic.es
Un paso más en el cáncer de mama triple negativo precoz: inmunoterapia Page 1 0213-8573
RC Copyright © 2023 AE , . . [R . C ; (S .1): ] El cáncer de mama triple negativo (CMTN) sigue …
Save Cite Related articles All 2 versions View as HTML